Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Is the universe infinite? It's one of the most profound questions we can ask, and here's the short answer: We don't know. While we have learned a great deal about the universe, a portion of the cosmos ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Halo Infinite had one of the best-feeling sandboxes in franchise history. The movement, the ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Microsoft has announced plans to put Halo Infinite into maintenance mode later this month so developer Halo Studios can focus on working on multiple new Halo games. In a blog post, Halo Studios said ...

Microsoft and Halo Studios are looking ahead to the future, but that future will not include new content for Halo Infinite. After four years, the latest installment of the Halo timeline appears poised ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...